Visium Asset Management’s Stemline Therapeutics STML Stock Holding History
Bought
Maintained
Sold
Other funds holding STML
BBA
Visium Asset Management's STML Position: Q4 2014 in Review
Visium Asset Management sold out of Stemline Therapeutics (STML) in Q4 2014, closing a stake of 150,000 shares — an estimated $1.87M sold.
Visium Asset Management first reported a position in STML in Q2 2013 and held it in 6 quarters. The position peaked at $7.15M in Q2 2013. 62 funds tracked by Wall St. Rank hold STML as of Q4 2014.
- Visium Asset Management reported no remaining Stemline Therapeutics position as of Q4 2014 after selling out during the quarter.
- Visium Asset Management sold 150,000 Stemline Therapeutics shares in Q4 2014, an estimated $1.87M.
- Visium Asset Management first reported a position in Stemline Therapeutics in Q2 2013 and held it in 6 quarters.
- Visium Asset Management's Stemline Therapeutics position peaked at $7.15M in Q2 2013.
- 62 funds tracked by Wall St. Rank held Stemline Therapeutics as of Q4 2014.
Based on Visium Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.